ArticleScience advances2026
An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy.
Taiana C Leite, Jue Hou, Xuehui Geng, Luigi Mancinelli, Abigail Sedlacek, Devanshi A Nayak, Karen E Schoedel, Kurt R Weiss, Robert J Binder, Charles P Lin and 1 more
Abstract read
In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Taiana C LeiteDepartment of Oral and Craniofacial Sciences, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-5435-2317 Jue HouCenter for Systems Biology and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4417-7134 Xuehui GengDepartment of Periodontics and Preventive Dentistry, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA.
Luigi MancinelliDepartment of Periodontics and Preventive Dentistry, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-7264-4978 Abigail SedlacekDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-5623-6723 Devanshi A NayakDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-7897-0758 Karen E SchoedelDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-5398-8962 Kurt R WeissHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Robert J BinderDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-0857-3949 Charles P LinCenter for Systems Biology and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7450-627X Giuseppe IntiniDepartment of Periodontics and Preventive Dentistry, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-6862-7040 Funding
(PQ7) A multi-fluorescent intravital microscopy approach to study osteosarcomaR21CA208618 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI INTINI, GIUSEPPE · 2017 to 2018
$368kNCI NIH HHS R21 CA208618
6 · The paper itselfAbstract
Despite substantial treatment improvements, the 5-year survival rate for metastatic osteosarcoma (OS) is still as low as 20%. Immunocompetent genetic mouse models of OS have been introduced, enabling in vivo OS studies. Here, we present the ROCCIA mouse, a quintuple-mutant extension of these models that develops multifluorescent OS tumors, allowing distinct fluorescently labeled OS cell populations to be identified and traced both within tumors and in the circulation. In addition, this model enables postnatal inactivation of the
Indexed as
Bone NeoplasmsOsteosarcomaAnimalsDisease Models, AnimalDisease ProgressionHumansLung NeoplasmsMiceNeoplasm MetastasisTumor MicroenvironmentTumor Suppressor Protein p53Tumor Suppressor Protein p53
Identifiers
PMID42826198
PMCPMC13632736
What OpenQuestion holds
Textmetadata
Read underepoch 390